ASK REDCHAT ANYTHING ABOUT ONCOLYTICS BIOTECH INC.
Oncolytics Biotech Inc. (NASDAQ: ONCY)
Listen to this Section
$0.88
-0.0040
(
-0.46% )
731.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Pelareorep + gemcitabine, nab-paclitaxel, atezolizumabDetailsCancer, Pancreatic cancer |
Phase 3 |
| Pelareorep + RetifanlimabDetailsBreast cancer, Triple-negative breast cancer |
Phase 2 |
| Pelareorep + paclitaxel + avelumab (Bavencio®)DetailsBreast cancer, Cancer |
Phase 2 |
| Pelareorep + Atezolizumab (Tecentriq)DetailsCancer, Anal cancer |
Phase 1/2 |
| Pelareorep + modified FOLFIRINOXDetailsPancreatic cancer, Cancer |
Phase 1/2 |
| Pelareorep +/- AtezolizumabDetailsCancer, Breast cancer |
Phase 1/2 |
| Pelareorep + Keytruda®DetailsPancreatic cancer, Sarcoma |
Failed |
Market Data
|
| Open |
$0.88 |
| Previous Close |
$0.88 |
| Volume |
731.5K |
| Market Cap |
$105.03M |
| Day Range |
$0.86 - $0.92 |
| 52 Week Range |
$0.33 - $1.51 |
| Shares Outstanding |
119.35M |
| Change % |
-0.46% |
| Net Change |
▼ -0.0040 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2001 |
| Country | Canada |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| schedule |
Other |
1 |
Nov 14, 2025 |
| 6-k |
Form 6-K |
6 |
Nov 12, 2025 |
| 6-k |
Form 6-K |
2 |
Nov 04, 2025 |
| 6-k |
Form 6-K |
2 |
Oct 28, 2025 |
| 6-k |
Form 6-K |
2 |
Oct 20, 2025 |
| 6-k |
Form 6-K |
3 |
Oct 20, 2025 |
| 6-k |
Form 6-K |
23 |
Oct 10, 2025 |
| 6-k |
Form 6-K |
2 |
Sep 29, 2025 |
| 6-k |
Form 6-K |
2 |
Sep 16, 2025 |
| 6-k |
Form 6-K |
2 |
Sep 08, 2025 |